Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

BACKGROUND: Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were excluded from the original nivolumab trials. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Koshkin, Vadim S., Barata, Pedro C., Zhang, Tian, George, Daniel J., Atkins, Michael B., Kelly, William J., Vogelzang, Nicholas J., Pal, Sumanta K., Hsu, JoAnn, Appleman, Leonard J., Ornstein, Moshe C., Gilligan, Timothy, Grivas, Petros, Garcia, Jorge A., Rini, Brian I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789686/
https://www.ncbi.nlm.nih.gov/pubmed/29378660
http://dx.doi.org/10.1186/s40425-018-0319-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789686/
https://www.ncbi.nlm.nih.gov/pubmed/29378660
http://dx.doi.org/10.1186/s40425-018-0319-9

Ejemplares similares